Compass Therapeutics, Inc. Cash And Cash Equivalents At Carrying Value

• Compass Therapeutics, Inc. showed a decrease of -29.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Compass Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
• XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 9 years of available data (2019 to 2025), Compass Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 629,637.0%.
• Historical annual values: Fiscal year 2025: $30.64 million | Fiscal year 2024: $43.48 million | Fiscal year 2023: $24.23 million | Fiscal year 2022: $34.95 million | Fiscal year 2021: $144.51 million | Fiscal year 2020: $47.08 million | Fiscal year 2020: $3.7 thousand | Fiscal year 2019: $25.30 million | Fiscal year 2019: $4.9 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026